These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16897662)

  • 21. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of prevalence, severity, and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus.
    Dutta SK; Ting CD; Lai LL
    Am J Gastroenterol; 1997 Nov; 92(11):2044-8. PubMed ID: 9362189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression.
    Nnoruka EN; Chukwuka JC; Anisuiba B
    Int J Dermatol; 2007 Oct; 46 Suppl 2():14-8. PubMed ID: 17958624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
    Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl.
    Mouala C; Guiguet M; Houzé S; Damond F; Pialoux G; Viget N; Costagliola D; Le Bras J; Matheron S;
    AIDS; 2009 Sep; 23(15):1997-2004. PubMed ID: 19654499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003.
    Barry PM; Zetola N; Keruly JC; Moore RD; Gebo KA; Lucas GM
    AIDS; 2006 Feb; 20(3):437-44. PubMed ID: 16439878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
    Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
    Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between clinical conditions and CD4 counts in HIV-infected persons in Pune, Maharashtra, India.
    Ghate MV; Mehendale SM; Mahajan BA; Yadav R; Brahme RG; Divekar AD; Paranjape RS
    Natl Med J India; 2000; 13(4):183-7. PubMed ID: 11002684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
    Podlekareva D; Mocroft A; Kirk O; Reiss P; Aldins P; Katlama C; Kovari H; Stellbrink HJ; D'Arminio Monforte A; Lundgren JD;
    Scand J Infect Dis; 2008; 40(11-12):908-13. PubMed ID: 18609197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
    J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
    Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
    AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
    Erice A; Tierney C; Hirsch M; Caliendo AM; Weinberg A; Kendall MA; Polsky B;
    Clin Infect Dis; 2003 Aug; 37(4):567-78. PubMed ID: 12905142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of oral candidiasis and oral hairy leukoplakia in HIV-infected adults in North Carolina.
    Chattopadhyay A; Caplan DJ; Slade GD; Shugars DC; Tien HC; Patton LL
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Jan; 99(1):39-47. PubMed ID: 15599347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
    Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
    AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults.
    Chattopadhyay A; Caplan DJ; Slade GD; Shugars DC; Tien HC; Patton LL
    Community Dent Oral Epidemiol; 2005 Feb; 33(1):35-44. PubMed ID: 15642045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups.
    Belanger F; Derouin F; Grangeot-Keros L; Meyer L
    Clin Infect Dis; 1999 Mar; 28(3):575-81. PubMed ID: 10194081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.